Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Arthritis Research & Therapy

Figure 1

From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Figure 1

Patient disposition. (a) Flow chart of patient disposition. A total of 596 patients were screened for this study, of which 575 started infliximab. Of these, 71 were lost to follow-up, so that 504 were evaluated. There were 158 patients that discontinued treatment before week 74, and the remaining 346 completed the study according to protocol and were still on infliximab at study end. 'Other' under treatment discontinuations included three patients that wished to become pregnant and one that withdrew prior to an elective surgery. (b) Patients remaining on infliximab at each visit. (c) Fraction of evaluable patients completing the study or discontinuing for safety reasons, inefficacy, or elective reasons.

Back to article page